Beyond Alternatives Exhibiting at Total Product Expo 2023
- S&P 500 and Nasdaq notch highest closes since early 2022
- U.S. economy adds 199,000 jobs in November
- Fed should 'lowball' rate cuts expectations next week says analyst after strong jobs data
- Bernstein's best idea for 2024? Short Tesla stock
- Analysts defend Broadcom as annual guidance falls short after FQ4 earnings beat
Beyond Alternatives LLC will have a booth at the three-day TPE event next week from February 22 to February 24; Beyond Alternatives LLC will continue introducing its inaugural brand “Jayvees” to the market at the exclusively B2B event
LAS VEGAS and VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is pleased to announce that its subsidiary Beyond Alternatives LLC (“Beyond Alternatives”) will be an exhibitor at the Total Product Expo (“TPE”), which is being held at the Las Vegas Convention Center from Wednesday, February 22, 2023 through Friday, February 24, 2023. Beyond Alternatives’ exhibit at TPE will be located at booth 2105. Earlier this month, Beyond Alternatives also exhibited at the CHAMPS Las Vegas trade show to launch its inaugural brand “Jayvees” (as announced in a press release dated February 6, 2023). At the CHAMPS trade show, the majority of Beyond Alternatives’ sales came from accounts which had previously done business with the Company and included positive responses to the new Jayvees products.
Previously known as “Tobacco Plus Expo”, TPE is a business-to-business (“B2B”) annual trade expo featuring thousands of products in categories to include tobacco and vaping, with the recent addition of gifts, snacks, and apparel. Along with the main three-day trade show, TPE also hosts an Industry Night Party for TPE badge holders. The 2023 TPE event has 30% more floor space than the 2022 event, including a dedicated space for new brands and product categories. More information about TPE can be found at the following link: https://totalproductexpo.com/
TAAT® Chief Executive Officer Michael Saxon commented, “Trade shows are an excellent way to meet buyers for independent and corporate retailers as well as distribution partners, which is why we are keen to build our presence in this circuit as Beyond Alternatives brings Jayvees to market as its inaugural brand. The TPE show, where the Company also exhibited in 2022, has expanded for the year 2023. Not just physically with 30% more floor space, but also in terms of the range of products on offer. Moving on from a specialty in tobacco products and titled ‘Tobacco Plus Expo’, TPE is now known as ‘Total Product Expo’ and is hosting vendors in added categories to include gifts, snacks, and apparel. I believe this aligns with the Company’s recent diversification of its own operations beyond a primary focus on tobacco alternatives. We are very much looking forward to Beyond Alternatives’ second trade show appearance in 2023 at next week’s TPE event.”
On behalf of the Board of Directors of the Company,
TAAT® GLOBAL ALTERNATIVES INC.
Michael Saxon, CEO and Director
For further information, please contact:
TAAT® Investor Relations1-833-TAAT-USA (1-833-822-8872)[email protected]
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT® Global Alternatives Inc.
TAAT® is a vertically integrated consumer product and distribution company, generating more than CAD $90 million in overall gross revenue annually. TAAT® is strategically expanding its product categories including tobacco and reduced-risk alternatives, hemp, kratom, and other emerging CPG segments. TAAT® has facilities to include a processing plant in Nevada as well as a distribution centre in Canton, Ohio, leveraging existing retail shelf space and pipelines into national wholesale channels.
For more information, please visit http://taatglobal.com.
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT® in the tobacco industry, in addition to the following: Potential outcomes from Beyond Alternatives’ exhibit at the TPE 2023 event in Las Vegas. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; (iii) changes to the regulatory landscape applicable to the Company's business; and (iv) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Statement Regarding Third-Party Investor Relations Firms
Disclosures relating to investor relations firms retained by TAAT® Global Alternatives Inc. can be found under the Company's profile on http://sedar.com.Source: TAAT Global Alternatives Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
- Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independ
- Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!